Dog and Cat Liver Biopsy Submission Form

Transcription

Dog and Cat Liver Biopsy Submission Form
Dog and Cat Liver Biopsy Submission Form
LAB USE ONLY
Animal Health Diagnostic Center
College of Veterinary Medicine, Cornell University
In Partnership with the NYS Dept. of Ag & Markets
US Postal Service Address: FedEx/UPS Service Address:
PO Box 5786
240 Farrier Rd.
Ithaca, NY 14852-5786
Ithaca, NY 14853
AHDC Contacts:
Phone: 607-253-3900
Fax: 607-253-3943
Web: ahdc.vet.cornell.edu
Email: [email protected]
AHDC Accession No. / Date
PLEASE NOTE: SAMPLES SUBMITTED FOR TESTING
BECOME THE PROPERTY OF THE ANIMAL HEALTH
DIAGNOSTIC CENTER AND MAY BE TESTED AS PART
OF STATE/FEDERAL SURVEILLANCE PROGRAMS.
PLEASE COMPLETE ALL FIELDS, PRINT LEGIBLY, AND ENTER ONLY ONE ANIMAL PER FORM
Check if STAT (Available Monday through Friday: Standard fee + add’l $30. Results are reported by telephone followed by a written report)
Digital Copper and Iron Quantification ($25 additional)
If this is a second opinion, please provide a copy of the original biopsy report.
AHDC Acct No.
Submitting Veterinarian*
Clinic Name
Address
City
Phone No.
Submitting Vet’s Signature
State
Fax No.
Your Internal Case/Reference No. **
Owner
Address
City
State
Phone No.
County
Town
NYS Premises ID
Zip
Zip
ANIMAL IDENTIFICATION
SEX CODES: M=Male, MR=Mare (equine only), MC=Castrated Male, F=Female, SF=Spayed Female
AGE CODES: Y=Years, M=Months, W =Weeks, D=Days; DOB=Date of Birth
NAME / IDENTIFIER NO.
SPECIES
BREED
Sampling
Date
Specimen and
Anatomical Site
Tests Requested
(Enter full name of tests)
SEX AGE / DOB
Other diagnostic tests requested:
Case Information: a copy of the medical record can be faxed to (607) 253-4299 or e-mailed to pathologyservicecornell.edu
Biochemistry Results (normal ranges or fold change)
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Total bilirubin
Bile acids (absolute value)
Protein C (absolute value)
Cholesterol
Indicate lesion location. Indicate biopsy location/technique.
Note: If sampling a mass, take an additional biopsy from an
unaffected liver lobe. If suspecting portal vein
hypoperfusion, avoid sampling the quadrate liver lobe.
Clinical / Differential Diagnosis:
Has related material been submitted
previously for this animal?
Yes
Accession No.
No
Clinical Summary (imaging findings, appearance, size, and lesion(s) distribution:
Check here if history is continued on next page, or if add’l history is attached
AHDC USE ONLY
OPENED BY:
FEDEX
FEDEX-GRND
UPS-GRND
UPS-ND
MAIL
PRI MAIL
EXP MAIL
OTHER:
DATE REC'D:_
TIME REC'D:_
DATESHIPPED:_
FROZEN
RM TEMP
COOL
COLD
* The submitting veterinarian is responsible for the requested tests, fees associated with this submission, and to notify the owner of test results.
**If your Internal Reference No. is entered on this form, it will be used to identify this case on the test result form and on the billing statement (max. 17 characters field)
DRY ICE
COLD PACK
NONE
COMMENT:_
Document Code: ORG-WEB-FORM-006-V01

Similar documents

Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026

Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026 Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.

More information